Abstract: Methods for predicting the activity of cellular constituents in a biological system are described. In particular, a method for predicting the potential biological activity of a cellular constituent for affecting a biological state is described. A method for identifying biological processes of a biological state modulated by a cellular constituent is also described. Also included is a method for predicting biological processes involved in the action of a drug.

Abstract: A transdermal drug delivery device that administers drug in an initial pulse followed by a substantially lower continuous rate comprising a drug reservoir of the drug dissolved in a nonvolatile skin permeation enhancer and a volatile permeation enhancer confined between a backing that is permeable to the volatile permeation enhancer and an underlying substrate layer that is permeable to the drug and both enhancers. When the device is placed on the skin the volatile permeation enhancer is depleted from the reservoir by evaporation through the backing such that the magnitude and duration of the pulse is dependent upon the permeability of the backing layer to the volatile enhancer.

Abstract: A transdermal drug delivery device that administers drug in an initial pulse followed by a substantially lower continuous rate comprising a drug reservoir of the drug dissolved in a carrier and a volatile permeation enhancer confined between a backing that is permeable to the volatile permeation enhancer and an underlying substrate layer that is permeable to the drug, carrier and enhancer. When the device is placed on the skin the volatile permeation enhancer is depleted from the reservoir by evaporation through the backing such that the magnitude and duration of the pulse is dependent upon the permeability of the backing layer to the volatile enhancer.

Abstract: A delayed onset transdermal drug delivery device exhibiting a delay period of at least eight hours comprising a laminated composite of (12) a top backing layer; (13) a pressure rupturable layer underlying (12); (14) a reservoir of a solution of drug in al liquid vehicle between (12) and (13); (16) a wick layer underlying (13) for dispersing the drug once (13) is ruptured; (17) a first adhesive layer underlying (16) that is permeable to the drug; (18) a first polymer membrane that is permeable to drug but substantially impermeable to the adhesive of (17); (19) a microporous membrane underlying (18) which is itself impermeable to the drug and whose pores are unfilled; (20) a second polymer membrane that underlies the microporous membrane that is permeable to drug but substantially impermeable to the adhesive of (21) below; and (21) a second adhesive layer underlying (20) that is permeable to the drug.

Abstract: A delayed onset transdermal drug delivery device exhibiting a delay period of at least six hours comprising a laminated composite of (12) a top backing layer; (13) a pressure rupturable layer underlying (12); (14) a reservoir of a solution of drug in a liquid vehicle between (12) and (13); (16) a wick layer underlying (13) for dispersing the drug once (13( is ruptured; (17) a polymer layer underlying (16) that is permeable to the drug; (18) a microporous membrane underlying (17) which is itself impermeable to the drug but whose pores are filled with a polymer that is immiscible in the adhesive and has a solubility parameter within two units of the solubility parameter of the vehicle; and (20) an adhesive layer underlying (18) that is permeable to the drug but is immiscible in the polymer filling the pores of (6).